cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Angion Biomedica Corp
13 own
9 watching
Current Price
$0.7
$0
(0%)
logo-angn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
21.08M
52-Week High
52-Week High
2.94
52-Week Low
52-Week Low
0.59
Average Volume
Average Volume
0.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization21.08M
icon52-Week High2.94
icon52-Week Low0.59
iconAverage Volume0.18M
iconDividend Yield--
iconP/E Ratio--
What does the Angion Biomedica Corp do?
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Read More
How much money does Angion Biomedica Corp make?
News & Events about Angion Biomedica Corp.
PR Newswire
2days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE PR Newswire NEW YORK, Jan. 26, 2023 NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following...
PR Newswire
6days ago
Moore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law Firm Moore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law Firm PR Newswire NEW YORK, Jan. 21, 2023 NEW YORK, Jan. 21, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation...
Globe Newswire
6days ago
NEW YORK, Jan. 21, 2023 (GLOBE NEWSWIRE) -- Golden Matrix Group, Inc. (NASDAQ: GMGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of GMGI and MeridianBet Group. If you are a GMGI investor, and would like additional information ...
Globe Newswire
7days ago
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire...
Business Wire
9days ago
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Angion Biomedica Corp (the Company) (NasdaqGS: ANGN) with Elicio Therapeutics pursuant to which Angion shareholders are expected to own...
Frequently Asked Questions
Frequently Asked Questions
What is Angion Biomedica Corp share price today?
plus_minus_icon
Can Indians buy Angion Biomedica Corp shares?
plus_minus_icon
How can I buy Angion Biomedica Corp shares from India?
plus_minus_icon
Can Fractional shares of Angion Biomedica Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Angion Biomedica Corp stocks?
plus_minus_icon
What is today’s traded volume of Angion Biomedica Corp?
plus_minus_icon
What is today’s market capitalisation of Angion Biomedica Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Angion Biomedica Corp?
plus_minus_icon
What percentage is Angion Biomedica Corp down from its 52-Week High?
plus_minus_icon
What percentage is Angion Biomedica Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$0.7
$0
(0%)
logo-angn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00